9. Taton O, Bondue B, Roufosse F. Hypereosinophilic syndromes and lung involvement. In: Jackson DJ, Wechsler ME, eds. Eosinophilic Lung Diseases (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 153–176. 10. Nanzer AM, Wechsler ME. Eosinophilic granulomatosis with polyangiitis. In: Jackson DJ, Wechsler ME, eds. Eosinophilic Lung Diseases (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 177–192. 11. De La Torre U, Fryer AD, Jacoby DB, et al. Eosinophils and airway nerves in asthma. In: Jackson DJ, Wechsler ME, eds. Eosinophilic Lung Diseases (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 193–203. 12. Dhariwal J, Padayachee Y, Johnston SL. Respiratory viruses and eosinophilic airway inflammation. In: Jackson DJ, Wechsler ME, eds. Eosinophilic Lung Diseases (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 204–218. 13. Mukherjee M, Nair P. Eosinophils as potential mediators of autoimmunity. In: Jackson DJ, Wechsler ME, eds. Eosinophilic Lung Diseases (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 219–237. 14. Jackson DJ, Munitz A. Safety of eosinophil depletion. In: Jackson DJ, Wechsler ME, eds. Eosinophilic Lung Diseases (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 238–252. 15. Lambrecht BN, Aegerter H, Schetters S, et al. Future prospects of translational and clinical eosinophil research. In: Jackson DJ, Wechsler ME, eds. Eosinophilic Lung Diseases (ERS Monograph). Sheffield, European Respiratory Society, 2022 pp. 253–262. Disclosures: D.J. Jackson reports receiving consulting and speaker honoraria/fees from GlaxoSmithKline, AstraZeneca, Sanofi, Boehringer Ingelheim, Teva and Chiesi. M.E. Wechsler reports receiving consulting honoraria/fees from GlaxoSmithKline, AstraZeneca, Sanofi, Regeneron, Boehringer Ingelheim, Teva, Sentien, Cohero, Genzyme, Novartis, Genentech, Restorbio, Equillium, Cytoreason, Cerecor, Sound Biologic, Incyte and Kinaset. https://doi.org/10.1183/2312508X.10021521 xi